Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and ...
Collaboration will support Controlled Human Infection Model (CHIM) studies to accelerate development of effective and affordable RSV vaccinesNantes, France and Heidelberg, Germany, October 8, 2024 ...
Respiratory viruses can remain hidden in immune cells in the lungs long after the initial symptoms of an infection have ...
GSK & ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024: London, UK Monday, October 14, 2024, 14:00 Hrs [IST] GSK plc and Vi ...
EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...
Colorado's health department is working to get more information out to the public about circulating respiratory viruses. It’s ...
Pfizer has reportedly ended its Phase II/III trials for sisunatovir, a promising RSV candidate acquired with ReViral in a ...
COVID-19 disrupted established patterns of seasonal transmission for several major respiratory Illnesses, with the exception of rhinovirus.
Hosted on MSN3d
What It’s Like to Have RSV as an Older AdultAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted ... You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a ...
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...
The effectiveness of the long-acting monoclonal antibody nirsevimab (Beyfortus) against primary care visits for lower ...
The Alberta government announced Monday that the RSV vaccine, Abyrsvo, will be provincially funded for Albertans, aged 60 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback